Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Opko Health Inc.

Start price
Target price
Perf. (%)
€1.14
27.12.22
-
27.12.23
11.81%
24.04.23

Risky Investment
buy
Mirati Therapeutics Inc.

Start price
Target price
Perf. (%)
€47.20
07.12.22
-
07.12.23
-16.53%
10.12.22

Risky Investment
buy
Syneos Health, Inc.

Start price
Target price
Perf. (%)
€26.12
04.11.22
-
04.11.23
23.91%
10.11.22

Risky Investment
buy
Davita Inc.

Start price
Target price
Perf. (%)
€73.02
28.10.22
-
0.45%
28.10.22

Risky Investment
Medpace Holdings Inc

Start price
Target price
Perf. (%)
€218.90
25.10.22
€190.00
25.10.23
11.47%
26.10.23

Could be worthwhile Investment >10% per year
buy
Invitae Corp

Start price
Target price
Perf. (%)
€2.14
16.10.22
-
16.10.23
-3.57%
18.02.23

Risky Investment
buy
Invitae Corp

Start price
Target price
Perf. (%)
€2.47
27.09.22
-
27.09.23
-13.02%
15.10.22

Risky Investment
buy
Blueprint Medicines Corp

Start price
Target price
Perf. (%)
€74.46
07.09.22
€100.00
31.12.24
-29.49%
05.05.23

Could be very worthwhile Investment >20% year
buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€208.80
07.09.22
€300.00
31.12.24
-33.67%
30.05.24

Could be very worthwhile Investment >20% year
buy
Glaukos Corp

Start price
Target price
Perf. (%)
€58.00
07.09.22
€63.00
07.09.23
-8.62%
08.05.23

Could be worthwhile Investment >10% per year
buy
Invitae Corp

Start price
Target price
Perf. (%)
€2.76
02.09.22
-
02.09.23
-10.51%
27.09.22

Could be very worthwhile Investment >20% year
buy
Invitae Corp

Start price
Target price
Perf. (%)
€3.32
26.08.22
-
26.08.23
-17.03%
03.09.22

Could be very worthwhile Investment >20% year
buy
Mirati Therapeutics Inc.

Start price
Target price
Perf. (%)
€76.50
21.08.22
€230.00
21.08.23
6.54%
04.09.22

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Probably not worthwhile Investment
Lower EBIT Margin than peer group
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€214.90
21.08.22
€87.00
21.08.23
-3.44%
04.09.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Invitae Corp

Start price
Target price
Perf. (%)
€3.50
21.08.22
€1.00
21.08.23
-21.28%
04.09.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
PTC Therapeutics Inc.

Start price
Target price
Perf. (%)
€51.50
16.08.22
-
16.08.23
-27.77%
16.08.23

buy
Neurocrine Bioscience

Start price
Target price
Perf. (%)
€104.86
16.08.22
-
16.08.23
-6.73%
16.08.23

buy
Global Blood Therapeutics Inc

Start price
Target price
Perf. (%)
€64.36
10.08.22
-
10.08.23
6.49%
10.08.23

buy
Amicus Therapeutics Inc.

Start price
Target price
Perf. (%)
€12.10
10.08.22
-
10.08.23
3.34%
10.08.23

buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€210.00
04.08.22
-
04.08.23
-17.71%
04.08.23

buy
Teladoc Health Inc

Start price
Target price
Perf. (%)
€34.89
29.07.22
-
29.07.23
-26.25%
29.07.23

buy
Invitae Corp

Start price
Target price
Perf. (%)
€2.86
12.07.22
€2.10
12.07.23
-54.35%
11.03.23

Could be worthwhile Investment >10% per year
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
Repligen Corp.

Start price
Target price
Perf. (%)
€173.28
09.07.22
-
09.07.23
-24.17%
09.07.23

buy
Bluebird Bio Inc.

Start price
Target price
Perf. (%)
€3.48
08.06.22
-
08.06.23
-14.83%
16.04.23

Risky Investment
buy
Bluebird Bio Inc.

Start price
Target price
Perf. (%)
€2.81
30.05.22
-
30.05.23
23.85%
08.06.22

Risky Investment